Stock Alert for Array BioPharma Inc. ($ARRY)
  • Stock Alert for BioPharma Inc. (AVII)
  • Stock Alert for Hemispherx BioPharma Inc. (HEB)
  • " />

    Stock Alert for Galena Biopharma Inc. (GALE)

    Shares in Galena Biopharma Inc. (GALE) is a biopharmaceutical company engaged in the development of innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care. The Company is pursuing the development of cancer therapeutics using peptide-based immunotherapy products, including its main product candidate, NeuVax (E75), for the treatment of various cancers. It is also developing Folate Binding Protein-E39 (FBP), a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial, and breast cancers.

    Share Statistics (22-Mar-12)   FY












    Symbol GALE Revenue, $Mn 0 0 0 0
    Current price $2.31 Gross marg.
    52wk Range: $0.36-$3.54 Oper. margin
    Avg Vol (3m): 1653320 Net margin
    Market Cap. 99.30M              
    Shares Outstanding 42.98M EPS, $ -1.24 -0.67 -46.00% -0.23 -0.13 -43.50%

    Source:, SEC Filings.

    Investment Highlights

    Shares in Galena Biopharma Inc. (GALE) slipped nearly 17% to close at $2.31, giving up big gains earlier this week when the biotechnology company announced a new patent on its cancer therapy NeuVax. Nearly 33 million shares exchanged hands during the session, topping the 10-day average of over 5 million shares. Earlier in the session, the stock hit a new 52-week high of $3.54.

    GALE shares have gained 59.3% in the last five days; 115.9% in the last month; and 90.9% year-to-date.

    In a statement, the Company stated that had received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent covering the use of NeuVax, a HER2/neu peptide vaccine, for inducing immunity to breast cancer recurrence in patients having low-to-intermediate IHC ratings of 1+ or 2+ and a FISH rating of less than about 2.0. These patients represent a significant unmet medical need, with as much as 50-75% of breast cancer patients who do not qualify for Roche’s breast cancer drug Herceptin, the report said.

    According to Mark J. Ahn Ph.D., president and CEO, this patent reinforces the Company’s pioneering role in advancing treatment to reduce recurrence rates for breast cancer survivors.  “This addition to our global portfolio allows us to further strengthen our value proposition and explore additional uses for NeuVax to advance care and build value for patients and shareholders.”

    GALE on Wednesday announced the addition of Dr. Hope Rugo to its scientific advisory board. “Dr. Rugo’s renowned expertise in breast cancer research and treatment will offer Galena Biopharma deep insight into crucial areas for our continued progress. It is imperative that we build a world-class SAB with key opinion leaders to ensure our progress in developing novel approaches to advancing breast cancer care, and we look forward to Dr. Rugo’s participation,” commented CEO Ahn.


    Financial Summary

    GALE reported a net loss of $5.5 million, or $0.13 per basic and diluted share, for the three months ended September 30, 2011, compared with a net loss of $4.1 million, or $0.23 per basic and diluted share, for the comparable period in 2010. Such increase in net loss was due to an increase in net loss from operations.

    The Company realized a net loss of $13.1 million, or $0.39 per basic and diluted share, for the nine months ended September 30, 2011, compared with a net loss of $10.2 million, or $0.57 per basic and diluted share, for the nine months ended September 30, 2010. GALE attributed the increase in net loss to a $2.1 million increase in net loss from operations and a decrease of $1.7 million of non-cash income as a result of the change in fair value of warrant liability, which was offset by an increase in non-cash income of $0.7 million related to a gain in the purchase price consideration liability and an increase in other income of $0.2 million from government grant monies received.

    GALE’s cash, cash equivalents and short-term investments totaled $15.7 million at September 30, 2011, compared with cash and cash equivalents of $6.9 million at December 31, 2010. This $8.8 million increase is attributable to the closing of two underwritten public offerings that provided net cash proceeds of approximately $18.2 million after underwriting fees and other estimated offering expenses (the March 2011 offering resulting in net proceeds of $7.3 million and the April 2011 offering resulting in net proceeds of $10.9 million), offset by net cash used in operating activities of $10.5 million for the nine months ended September 30, 2011.


    Financial Strength (22-Mar-2012)




    Quick Ratio (MRQ) 3.37 1.42
    Current Ratio (MRQ) 0.75 4.17 1.75
    LT Debt to Equity (MRQ) 0.30 30.08 27.26
    Total Debt to Equity (MRQ) 1.68 33.11 36.25
    Interest Coverage (TTM) 51.21 2.32

    Source:, SEC Filings.

    Technical Analysis


    GALE is presently near its upper Bollinger Band. This suggests that it is at a high level relative to recent action.

    The MACD for GALE currently indicates a strong bullish signal for two reasons. First, the MACD is above the signal line, a 9-day moving average. Second, the MACD is above 0, which implies that the underlying moving averages are trending higher.

    Comparative Analysis

    Company Name Ticker Price per Mrkt. Cap. P/E P/S
    Mar22-2012 symbol Share, $ $ Mn 2011 2012 2011 2012
    Rosetta Genomics Ltd. (USA) ROSG 0.39 n/a n/a n/a n/a n/a
    Alnylam Pharmaceuticals Inc. ALNY 11.3 488.25M n/a n/a 8.19 16.46
    Biotechnology Median       17.45 n/a 9.23 n/a
    Galena Biopharma Inc. GALE 2.31% 99.30M n/a n/a n/a 49.65

    Source: Thomson Financial

    DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority.  We are neither licensed nor qualified to provide investment advice.

    The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice.  The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities.  We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.

    Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company.  An individual should never invest in the securities of any of the companies profiled based solely on information contained in our report.  Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.

    Any individual who chooses to invest in any securities should do so with caution.  Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested.  Always research your own investments and consult with a registered investment advisor or licensed stock broker before investing.

    Information contained in our report will contain “forward looking statements” as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934.  Subscribers are cautioned not to place undue reliance upon these forward looking statements.  These forward looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated.  Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company’s most recent reports or registration statements filed with the SEC.  You should consider these factors in evaluating the forward looking statements included in the report and not place undue reliance upon such statements.

    We are committed to providing factual information on the companies that are profiled.  However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company’s plans or ability to effect any planned or proposed actions.  We have no first-hand knowledge of any profiled company’s operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so.  Statistical information, dollar amounts, and market size data was provided by the subject company and related sources which we believe to be reliable.

    To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information).

    We encourage you to invest carefully and read investment information available at the websites of the SEC at and FINRA at

    Leave a Reply

    Your email address will not be published. Required fields are marked *